Navigation Links
Studies Show Mild Hyperthermia Enhances Antitumor Effects of,Alfacell's Onconase

ry_hl=1&itool=pubmed_docsum.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon t
'"/>




Page: 1 2 3

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:12/16/2009)... Inc. (Pink Sheets: AVXT) ("AVAX" or the "Company") ... loan financing (the "2009 Financing") pursuant to a ... with Firebird Global Master Fund, Ltd., ("Firebird"). Pursuant ... promissory note, due June 30, 2010, in the ... warrant to purchase an aggregate of 93,333,333 shares ...
(Date:12/16/2009)... -- Cohera Medical Inc. today announced the treatment ... its lead surgical adhesive product, TissuGlu®. Initiation of ... company,s progression of the lead product toward clinical ... prospective, open-label, randomized study to investigate the safety ... and associated complications in abdominoplasty, or "tummy tuck," ...
(Date:12/16/2009)... Wash., Dec. 16 Verathon®, maker ... to announce that portable bladder volume ultrasound ... CDC guidelines for the Prevention of Catheter-Associated ... CDC guidelines, introduced in early November 2009, ... to 1981. The guidelines are located ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Go Healthys Marquis Product Cholesterade 28R 29 at Your Fingertips on Google 53590 1Go Healthys Marquis Product Cholesterade 28R 29 at Your Fingertips on Google 53590 2Motorcyclist Lives On Rides On Through Organ Donation 53587 1Motorcyclist Lives On Rides On Through Organ Donation 53587 2Motorcyclist Lives On Rides On Through Organ Donation 53587 3Motorcyclist Lives On Rides On Through Organ Donation 53587 4Motorcyclist Lives On Rides On Through Organ Donation 53587 5CorVel Announces Revenues and Earnings 53584 1CorVel Announces Revenues and Earnings 53584 2CorVel Announces Revenues and Earnings 53584 3CorVel Announces Revenues and Earnings 53584 4CorVel Announces Revenues and Earnings 53584 5
... 25 DOV Pharmaceutical,Inc. ("DOV", or the "Company") ... Ib results for DOV 21,947, its lead triple ... obesity. A,preliminary analysis of the study results demonstrated ... doses examined, and produced a statistically,significant reduction in ...
... Novel SiRNA Approaches To Noise- Induced Hearing ... The, Prevention Of Chemotherapy-Induced Hearing Loss ... 24 Quark Pharmaceuticals, Inc.,a clinical-stage biopharmaceutical company ... announced today that,it has signed a collaboration agreement ...
Other Medicine Technology:DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 2DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 3DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 4DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 5Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss 2Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss 3
(Date:12/17/2009)... complex personal injury and insurance cases, recognized for exceptional appellate work ... ... Nexis) December 17, 2009 -- Jody Nathan , a respected ... injury and insurance coverage disputes, has been named by Oklahoma Super ... of Oklahoma for 2009-2010., , ,Only five percent of the lawyers ...
(Date:12/16/2009)... Custom Tops , a local business specializing in granite ... Country Home Health, a slider-eating throwdown at the neighborhood ... showed up to cheer on the two brave contestants ... support of the local charity, The Austin Children,s Shelter. ... who could eat the most burgers became an act ...
(Date:12/16/2009)... minorities might not gain full benefit from breakthroughs, experts ... embryonic stem cell lines currently used for research come ... , That could mean that non-whites will benefit less ... down the line, experts say. , Blacks could be ... used stem cell lines studied showed any traces of ...
(Date:12/16/2009)... most widely used human embryonic stem cell lines lack ... that must be addressed to ensure that all sectors ... a University of Michigan research team. ,, In the ... analyzed 47 embryonic stem cell lines, including most of ... scientists determined the genetic ancestry of each line and ...
(Date:12/16/2009)... reducing inflammation in the lungs , , WEDNESDAY, Dec. 16 ... role in inflammation seems to protect the lungs of ... , Researchers also found that adult smokers with this ... of developing chronic obstructive pulmonary disease (COPD), a progressive ... seems to be protective of the lungs in both ...
Breaking Medicine News(10 mins):Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:Most Stem Cells Used in Research Come From Whites 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3
... inhibits abnormal cells, study finds , , MONDAY, July 7 ... and red wine suppresses abnormal cell formation that leads ... researchers. , The compound, resveratrol, is sold in extract ... through a multi-stage process that differs depending on the ...
... Reduce Blood Pressure, NASHVILLE, Tenn., July 7 ... such as potassium, and possibly magnesium,and calcium by dietary ... and,decrease blood pressure in people with hypertension. A high ... the risk of coronary heart disease and,stroke. These findings ...
... Pa., July 7 /Xinhua-PRNewswire/ -- BMP Sunstone,Corporation ... today,announced that it received the New Business ... with foreign investment in the People,s,Republic of ... and,Commerce (SHAIC). With receipt of this license, ...
... NEW YORK, July 7 Many people ... complication associated with diabetes -- serious gum,disease. ... health and diabetes., Listen to ... Registered journalists can access video, audio, ...
... 7 Please attribute the,following statement to ... Science and Experimentation:, "This proposal is ... language to mislead the voters. This proposal,will ... embryos., This proposal does not ban ...
... and recognized 10,000,physicians across the U.S., WASHINGTON, July ... with a simple idea and an experiment that incentives ... Now as,part of a growing movement referred to as ... anniversary as the nation,s first and,largest effort to reward ...
Other Medicine News:Health News:Dietary Supplement May Prevent Breast Cancer 2Health News:Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 2Health News:Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 3Health News:BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd 2Health News:Bridges to Excellence Marks Five-Year Anniversary 2Health News:Bridges to Excellence Marks Five-Year Anniversary 3
Freedom Cath® is a latex, self-adhering, one-piece catheter designed for everyday wear....
The Freedom Clear catheter is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for every day wear....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
Medicine Products: